FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2616-2618 December 15, 2005 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Reid, I. R. PubMed Citation

To the Editor: Reid et al. (Sept. 1 issue)¹ compare a single infusion of 5 mg of zoledronic acid with 30 mg per day of oral risedronate for 60 days, showing the advantage of zoledronic acid over risedronate in the treatment of Paget's disease. Previously, Reid et al. reported on the efficacy and safety of oral alendronate at a dose of 40 mg per day.² Others have shown that oral alendronate at 40 mg per day was effective but associated with side effects.^3,4 However, considerable improvement in biochemical markers was shown even with 5 mg of oral alendronate per day.⁵ . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.